JNJ
New target, same old giant
Bank of America just nudged Johnson & Johnson’s price target up to $254, which is basically Wall Street’s way of saying, “Yep, the mega-cap healthcare machine still has gas in the tank.”
Why the Street is leaning in
This isn’t happening in a vacuum. J&J recently posted a Q1 EPS beat of $2.70 on $24.06 billion in revenue, then turned around and raised FY2026 EPS guidance to $11.45–$11.65. In other words: the company didn’t just clear the bar, it moved the bar and then asked for another plate.
Dividend royalty vibes
And because J&J apparently doesn’t know how to be boring in a normal way, it also increased its quarterly dividend for the 64th straight year. That kind of streak is catnip for income investors — the corporate equivalent of showing up to the marathon in loafers and still finishing near the front.
What it means for you
For shareholders, a higher price target after a beat-and-raise quarter usually reinforces the bull case:
- earnings momentum is still intact
- guidance is edging higher
- the dividend keeps doing its cozy, dependable thing
Big picture: J&J isn’t a flashy rocket ship. It’s more like a well-built cargo plane — not sexy, but when the engines are humming and analysts keep lifting targets, investors tend to pay attention.